These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 32925287

  • 1. Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase III China-centric study, MEASURE 5.
    Huang F, Sun F, Wan WG, Wu LJ, Dong LL, Zhang X, Kim TH, Sengupta R, Šenolt L, Wang Y, Qiu HM, Porter B, Haemmerle S.
    Chin Med J (Engl); 2020 Nov 05; 133(21):2521-2531. PubMed ID: 32925287
    [Abstract] [Full Text] [Related]

  • 2. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.
    Pavelka K, Kivitz A, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, Pricop L, Andersson M, Readie A, Porter B.
    Arthritis Res Ther; 2017 Dec 22; 19(1):285. PubMed ID: 29273067
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies.
    Wei JC, Baeten D, Sieper J, Deodhar A, Bhosekar V, Martin R, Porter B.
    Int J Rheum Dis; 2017 May 22; 20(5):589-596. PubMed ID: 28544533
    [Abstract] [Full Text] [Related]

  • 4. 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial.
    Marzo-Ortega H, Sieper J, Kivitz AJ, Blanco R, Cohen M, Pavelka K, Delicha EM, Stefanska A, Richards HB, Rohrer S.
    Lancet Rheumatol; 2020 Jun 22; 2(6):e339-e346. PubMed ID: 38273597
    [Abstract] [Full Text] [Related]

  • 5. Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
    Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB, MEASURE 1 Study Group, MEASURE 2 Study Group.
    N Engl J Med; 2015 Dec 24; 373(26):2534-48. PubMed ID: 26699169
    [Abstract] [Full Text] [Related]

  • 6. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.
    Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landewé R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Wei J, Brachat A, Bek S, Laurent D, Li Y, Wang YA, Bertolino AP, Gsteiger S, Wright AM, Hueber W.
    Lancet; 2013 Nov 23; 382(9906):1705-13. PubMed ID: 24035250
    [Abstract] [Full Text] [Related]

  • 7. Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study.
    Marzo-Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Martin R, Readie A, Richards HB, Porter B, Measure 2 Study Group.
    Arthritis Care Res (Hoboken); 2017 Jul 23; 69(7):1020-1029. PubMed ID: 28235249
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study.
    Kivitz AJ, Wagner U, Dokoupilova E, Supronik J, Martin R, Talloczy Z, Richards HB, Porter B.
    Rheumatol Ther; 2018 Dec 23; 5(2):447-462. PubMed ID: 30121827
    [Abstract] [Full Text] [Related]

  • 9. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study.
    Baraliakos X, Braun J, Deodhar A, Poddubnyy D, Kivitz A, Tahir H, Van den Bosch F, Delicha EM, Talloczy Z, Fierlinger A.
    RMD Open; 2019 Dec 23; 5(2):e001005. PubMed ID: 31565244
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J).
    Kishimoto M, Taniguchi A, Fujishige A, Kaneko S, Haemmerle S, Porter BO, Kobayashi S.
    Mod Rheumatol; 2020 Jan 23; 30(1):132-140. PubMed ID: 30334633
    [Abstract] [Full Text] [Related]

  • 11. Secukinumab Demonstrates Sustained Efficacy and Safety in a Taiwanese Subpopulation With Active Ankylosing Spondylitis: Four-Year Results From a Phase 3 Study, MEASURE 1.
    Tseng JC, Wei JC, Deodhar A, Martin R, Porter B, McCreddin S, Talloczy Z.
    Front Immunol; 2020 Jan 23; 11():561748. PubMed ID: 33324394
    [Abstract] [Full Text] [Related]

  • 12. Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study.
    Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P, Readie A, Martin R, Mpofu S, Richards HB, MEASURE 1 study group.
    Ann Rheum Dis; 2017 Jun 23; 76(6):1070-1077. PubMed ID: 27965257
    [Abstract] [Full Text] [Related]

  • 13. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study.
    Sieper J, Deodhar A, Marzo-Ortega H, Aelion JA, Blanco R, Jui-Cheng T, Andersson M, Porter B, Richards HB, MEASURE 2 Study Group.
    Ann Rheum Dis; 2017 Mar 23; 76(3):571-592. PubMed ID: 27582421
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial.
    Bao C, Huang F, Khan MA, Fei K, Wu Z, Han C, Hsia EC.
    Rheumatology (Oxford); 2014 Sep 23; 53(9):1654-63. PubMed ID: 24729398
    [Abstract] [Full Text] [Related]

  • 15. Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study.
    Braun J, Baraliakos X, Deodhar A, Poddubnyy D, Emery P, Delicha EM, Talloczy Z, Porter B.
    Rheumatology (Oxford); 2019 May 01; 58(5):859-868. PubMed ID: 30590813
    [Abstract] [Full Text] [Related]

  • 16. Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2.
    Marzo-Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Delicha EM, Rohrer S, Richards H.
    RMD Open; 2017 May 01; 3(2):e000592. PubMed ID: 29435364
    [Abstract] [Full Text] [Related]

  • 17. Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study.
    Pavelka K, Kivitz AJ, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, Wang Y, Porter BO, Stefanska A, Richards HB, Rohrer S, MEASURE 3 study group.
    ACR Open Rheumatol; 2020 Feb 01; 2(2):119-127. PubMed ID: 31957970
    [Abstract] [Full Text] [Related]

  • 18. Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long-Term Results of Two Phase III Randomized Controlled Trials.
    Kvien TK, Conaghan PG, Gossec L, Strand V, Østergaard M, Poddubnyy D, Williams N, Porter B, Shete A, Gilloteau I, Deodhar A.
    Arthritis Care Res (Hoboken); 2022 May 01; 74(5):759-767. PubMed ID: 33227175
    [Abstract] [Full Text] [Related]

  • 19. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.
    Deodhar A, van der Heijde D, Gensler LS, Kim TH, Maksymowych WP, Østergaard M, Poddubnyy D, Marzo-Ortega H, Bessette L, Tomita T, Leung A, Hojnik M, Gallo G, Li X, Adams D, Carlier H, Sieper J, COAST-X Study Group.
    Lancet; 2020 Jan 04; 395(10217):53-64. PubMed ID: 31813637
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.